Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
MicroStrategy (MSTR) Pops 3% After Saylor Announces 10 For 1 Stock Split
MicroStrategy (MSTR) Pops 3% After Saylor Announces 10 For 1 Stock Split

MicroStrategy will soon be far cheaper for smaller investors to gain exposure to.

Cryptopotato·2024/07/11 22:10
Shiba Inu (SHIB) ETF: The Pros and Cons According to Team Member
Shiba Inu (SHIB) ETF: The Pros and Cons According to Team Member

Here are the advantages and disadvantages that a potential SHIB ETF could provide.

Cryptopotato·2024/07/11 20:25
Why the Litecoin (LTC) price remains stagnant despite wide use
Why the Litecoin (LTC) price remains stagnant despite wide use

Share link:In this post: Litecoin sees significant turnover, moving up to 60% of its supply in a single day. LTC prices stagnated, with short positions dominating on most exchanges. Miners keep their activity at an all-time high, not capitulating despite low LTC prices.Disclaimer. The information provided is not trading advice. Cryptopolitan.com holds no liability for any investments made based on the information provided on this page. We strongly recommend independent research and/or consultation with a q

Cryptopolitan·2024/07/11 16:10
Story Protocol plans to launch IP-focused Layer 1 this year
Story Protocol plans to launch IP-focused Layer 1 this year

Quick Take Blockchain startup Story is coming out of stealth with its bespoke Layer 1 network built for IP management. The project is backed by investors including Paris Hilton’s 11:11 Media, Samsung Ventures and Andreessen Horowitz. Story is using an EVM-compatible blockchain together with a custom “Proof-of-Creativity” consensus algorithm.

The Block·2024/07/11 14:46
U.S. inflation falls to 3%, lowest level since 2021
U.S. inflation falls to 3%, lowest level since 2021

Share link:In this post: U.S. inflation dropped to 3% in June, the lowest since 2021, raising hopes for potential Federal Reserve interest rate cuts. The unemployment rate rose to 4.1%, the highest since the pandemic, causing concerns despite no immediate recession threat. Treasury yields fell, and stock futures rose after the CPI data release, with traders betting on interest rate cuts this year.Disclaimer. The information provided is not trading advice. Cryptopolitan.com holds no liability for any invest

Cryptopolitan·2024/07/11 14:07
Flash
14:37
Ventuals: HIP-3DEX Fully Closed, vHYPE Withdrawal Now Available
BlockBeats News, June 19th, Ventuals announced that HIP-3 DEX has been fully shut down, and vHYPE withdrawals have now begun. Approximately 380,775 HYPE in the full withdrawal queue was processed around 10 a.m. EST today. Previously queued vHYPE withdrawals were all included in this batch processing. Ventuals advised all vHYPE holders to initiate withdrawals, stating that 100% of vHYPE holders can redeem their HYPE at a 1:1 ratio and receive accrued native staking rewards since deposit.
14:36
Economist: Spending in Canada shows significant weakness excluding cars and gasoline
Jasleen Trehan, an economist at the Canadian Chamber of Commerce, stated that Canadians' spending on daily categories such as groceries and general merchandise weakened significantly in April. Nominal retail sales grew by 0.5% in April, but core sales excluding autos and gasoline declined by 0.7%. Trehan said that the estimated growth for May shows signs of consumer resilience, but given the weakness in the labor market, lingering uncertainty over U.S. trade policy, and concerns about energy-driven inflation, the path ahead remains uncertain.
14:33
According to the Financial Times, ongoing negotiations reveal that pharmaceutical giant AbbVie plans to acquire shareholders' equity in biotech company Apogee Therapeutics for a total of $10.9 billion in cash.
If this move is ultimately implemented, it will mark AbbVie's further strengthening of its presence in the innovative biologics sector beyond its core immunology field. Market analysts point out that this potential massive deal highlights large pharmaceutical companies’ strong desire to acquire biotech firms with promising pipelines, aiming to supplement their own product portfolios and drive future growth. Currently, neither party has formally commented on the transaction details, and subsequent developments are worth close attention.
News